## TABLE OF CONTENTS

### HIGHLIGHTS

#### 761
Selected Articles from This Issue

### SMALL MOLECULE THERAPEUTICS

#### 763
**Discovery of JNJ-63576253, a Next-Generation Androgen Receptor Antagonist Active Against Wild-Type and Clinically Relevant Ligand Binding Domain Mutations in Metastatic Castration-Resistant Prostate Cancer**

#### 775
**The Discovery of a Novel Antimetastatic Bcl3 Inhibitor**

#### 787
**The Monoacylglycerol Lipase Inhibitor JZL184 Inhibits Lung Cancer Cell Invasion and Metastasis via the CB1 Cannabinoid Receptor**
Jan Lukas Prüser, Robert Ramer, Felix Wittig, Igor Ivanov, Jutta Merkord, and Burkhard Hinz

#### 803
**Targeting EYA3 in Ewing Sarcoma Retards Tumor Growth and Angiogenesis**
A C Yuhua Wang, Ram Naresh Pandey, Kaushik Roychoudhury, David Milewski, Tanya V. Kalin, Sara Szabo, Joseph G. Pressey, and Rashmi S. Hegde

#### 816
**Identification and Characterization of IMD-0354 as a Glutamine Carrier Protein Inhibitor in Melanoma**
Yongmei Feng, Gaurav Pathria, Susanne Heynen-Genel, Michael Jackson, Brian James, Jun Yin, David A. Scott, and Ze’ev A. Ronai

### LARGE MOLECULE THERAPEUTICS

#### 833
**Taxanes Sensitize Prostate Cancer Cells to TRAIL-Induced Apoptotic Synergy via Endoplasmic Reticulum Stress**
Korie A. Grayson, Jacob M. Hope, Wenjun Wang, Cynthia A. Reinhart-King, and Michael R. King

#### 846
**Robust Antitumor Activity and Low Cytokine Production by Novel Humanized Anti-CD19 CAR T Cells**

#### 859
**A Novel Antibody–IL15 Fusion Protein Selectively Localizes to Tumors, Synergizes with TNF-based Immunocytokine, and Inhibits Metastasis**
Riccardo Corbellari, Marco Stringhini, Jaqueline Mock, Tiziano Ongaro, Alessandra Villa, Dario Neri, and Roberto De Luca

#### 872
**Shaping Functional Avidity of CAR T Cells: Affinity, Avidity, and Antigen Density That Regulate Response**
Raanan Greenman, Yoav Pizem, Maya Haus-Cohen, Alona Goor, Guy Horev, Galit Denker, Keren Sinik, Yael Elbaz, Vered Bronner, Anat Glieberson Levin, Galit Horn, Shai Shen-Orr, and Yoram Reiter

See related article, p. 946

#### 885
**Dolaflexin: A Novel Antibody–Drug Conjugate Platform Featuring High Drug Loading and a Controlled Bystander Effect**
A C Aleksandr V. Yurkovetskiy, Natalya D. Bodjak, Mao Yin, Joshua D. Thomas, Susan M. Clardy, Patrick R. Conlon, Cheri A. Stevenson, Alex Uttrd, LiuLiang Qin, Dmitry R. Gumerov, Elena Ter-Ovanesyan, Charlie Bu, Alex J. Johnson, Venu R. Gujrjala, Dennis McGillicuddy, Michael J. DeVit, Laura L. Poling, Marina Protopopova, Ling Xu, Qingxu Zhang, Peter U. Park, Donald A. Bergstrom, and Timothy B. Lowinger
### TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>896</td>
<td>The Dolaflexin-based Antibody-Drug Conjugate XMT-1536 Targets the Solid Tumor Lineage Antigen SLC34A2/NaPi2b</td>
</tr>
<tr>
<td>906</td>
<td>Interleukin-4 Receptor Inhibition Targeting Metastasis Independent of Macrophages</td>
</tr>
<tr>
<td>915</td>
<td>Antitumor Activity of NLG207 (Formerly CRLX101) in Combination with Enzalutamide in Preclinical Prostate Cancer Models</td>
</tr>
<tr>
<td>925</td>
<td>Preclinical Assessment of AMG 596, a Bispecific T-cell Engager (BiTE) Immunotherapy Targeting the Tumor-specific Antigen EGFRvIII</td>
</tr>
</tbody>
</table>

### CANCER BIOLOGY AND TRANSLATIONAL STUDIES

- **PGE2 Released by Pancreatic Cancer Cells Undergoing ER Stress Transfers the Stress to DCS Impairing Their Immune Function**
  - Maria Saveria Gilardini Montani, Rossella Benedetti, Silvia Piconese, Fabio Maria Pulcinelli, Anna Maria Timperio, Maria Anele Romeo, Laura Masuelli, Maurizio Mattei, Roberto Bei, Gabriella D’Orazi, and Mara Cirone

### MODELS AND TECHNOLOGIES

- **Phenotypic Models of CAR T-Cell Activation Elucidate the Pivotal Regulatory Role of CAR Downmodulation**
  - Raanan Greenman, Yoav Pizem, Maya Haus-Cohen, Guy Horev, Galit Denkberg, Shai Shen-Orr, Jacob Rubinstein, and Yoram Reiter
  - See related article, p. 872

### ABOUT THE COVER

In this month’s cover, Dwivedi and colleagues demonstrate the binding of a single chain variable fragment (scFv) of the humanized anti-CD19 CAR with CD19 target antigen, obtained through molecular modelling. The unique composition of amino acid residues of the framework region as well as the complementary determining regions (CDRs) of the scFv resulted into the scFv interaction to the CD19 antigen with high binding affinity and with high structural flexibility. Further preclinical and ex vivo studies confirmed that the distinct structural modification in CAR design confers the novel humanized anti-CD19 CAR with a favorable balance of efficacy to toxicity. Read the article on page 846.
Molecular Cancer Therapeutics

20 (5)

Mol Cancer Ther 2021;20:761-957.

Updated version
Access the most recent version of this article at:
http://mct.aacrjournals.org/content/20/5

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link
http://mct.aacrjournals.org/content/20/5.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.